UroGen Pharma (URGN) Cash & Equivalents Growth (3y) (2019 - 2026)

UroGen Pharma (URGN) Cash & Equivalents Growth (3y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -15.41%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 8.23%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 47.78%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 14.34%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 10.62%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -27.97%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 37.45%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -3.85%
10 UroGen Pharma 2.36 Bn 2.25 Bn 65.88 Mn 57.83%

Historic Data

Download Data
DateValue
Jun 30, 2026 57.83%
Mar 31, 2026 44.38%
Dec 31, 2025 25.97%
Sep 30, 2025 46.42%
Jun 30, 2025 25.99%
Mar 31, 2025 -0.43%
Dec 31, 2024 57.10%
Sep 30, 2024 31.18%
Jun 30, 2024 51.45%
Mar 31, 2024 48.06%
Dec 31, 2023 21.58%
Sep 30, 2023 69.35%
Jun 30, 2023 -17.88%
Mar 31, 2023 11.35%
Dec 31, 2022 3.70%
Sep 30, 2022 -24.31%
Jun 30, 2022 -19.91%
Mar 31, 2022 -24.69%
Dec 31, 2021 -24.07%
Sep 30, 2021 -20.34%